{
    "info": {
        "nct_id": "NCT03215264",
        "official_title": "Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",
        "inclusion_criteria": "* Histologic or cytologic confirmation of metastatic colorectal cancer\n* Measurable disease based on modified RECIST 1.1 criteria\n* Patients should have received adequate therapy with prior 5-fluorouracil, oxaliplatin, and irinotecan, unless contra-indicated, not tolerated or declined.\n* No prior therapy with regorafenib or other anti-angiogenic tyrosine kinase inhibitor\n* No prior or current therapy with an HDAC inhibitor\n* Age 18 years or older\n* ECOG performance status of 0 or 1\n* If a female of childbearing potential, has a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug. If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required. If a patient is of childbearing potential the patient must agree to use effective contraception (see Appendix C for acceptable methods) during the study and for 120 days after the last dose of study drug. Non-childbearing potential is defined as (by other than medical reasons):\n* ≥45 years of age and has not had menses for >2 years\n* Amenorrheic for <2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation\n* Post hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study drug\n* If male, agrees to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug\n* Life expectancy of greater than 3 months\n* Patients must have the ability to understand and the willingness to sign a written informed consent document.\n* Adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements within 4 weeks of starting treatment\n\n  * Absolute neutrophil count >1,500 per uL\n  * Hemoglobin > 9 g/dL\n  * Platelets >100,000 per uL\n  * Creatinine < 1.5 x ULN OR Creatinine clearance (CrCl) > 60 by Cockcroft-Gault Equation if Creatinine >1.5\n  * AST and ALT < 2.5 x ULN (< 5 x ULN if documented liver metastases)\n  * Total bilirubin <1.5 ULN OR direct bilirubin < ULN if total bilirubin > 1.5 x ULN\n  * INR < 2.0\n* Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade <1 (except alopecia or neuropathy). If patient underwent major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.\n\nExclusion Criteria\n\n* History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:\n\n  1. Myocardial infarction or arterial thromboembolic events within 6 months prior to screening or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc interval > 470 msec.\n  2. Uncontrolled hypertension or diabetes mellitus.\n  3. Another known malignancy that is progressing or requires active treatment.\n  4. Any prior history of other cancer within the prior 5 years with the exception of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ).\n  5. Active infection requiring systemic therapy\n  6. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.\n* Allergy to benzamide, inactive components of entinostat, or any of the other administered therapies\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.\n* If female, is pregnant or breastfeeding.\n* Known G6PD deficiency, severe psoriasis, porphyria, macular degeneration, or severe diabetic retinopathy due to greater potential HCQ toxicity\n* Patients with pre-existing hypertension should be on a stable antihypertensive regimen and have a blood pressure ≤ 150/100 mmHg at the time of enrollment.\n* Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication\n* Non-healing wound, ulcer, or bone fracture\n* Patients using warfarin are excluded. Patients using other oral or parenteral anticoagulation are not excluded provided they are on a stable dose of anticoagulant but must undergo more frequent platelet count monitoring.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* ≥45 years of age and has not had menses for >2 years",
            "criterions": [
                {
                    "exact_snippets": "≥45 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not had menses for >2 years",
                    "criterion": "menses",
                    "requirements": [
                        {
                            "requirement_type": "absence_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allergy to benzamide, inactive components of entinostat, or any of the other administered therapies",
            "criterions": [
                {
                    "exact_snippets": "Allergy to benzamide",
                    "criterion": "allergy to benzamide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Allergy to ... inactive components of entinostat",
                    "criterion": "allergy to inactive components of entinostat",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Allergy to ... any of the other administered therapies",
                    "criterion": "allergy to other administered therapies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If male, agrees to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "If male, agrees to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug",
                    "criterion": "contraception use (males)",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "agreement to contraception use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from first dose"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 120,
                                        "unit": "days after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements within 4 weeks of starting treatment",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone-marrow ... as assessed by the following laboratory requirements",
                    "criterion": "bone-marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... liver ... as assessed by the following laboratory requirements",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function as assessed by the following laboratory requirements",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Uncontrolled hypertension or diabetes mellitus.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... diabetes mellitus",
                    "criterion": "diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin <1.5 ULN OR direct bilirubin < ULN if total bilirubin > 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin <1.5 ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin < ULN if total bilirubin > 1.5 x ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "conditional",
                            "expected_value": "only if total bilirubin > 1.5 x ULN"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of greater than 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of greater than 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have the ability to understand and the willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior therapy with regorafenib or other anti-angiogenic tyrosine kinase inhibitor",
            "criterions": [
                {
                    "exact_snippets": "No prior therapy with regorafenib",
                    "criterion": "prior therapy with regorafenib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No prior therapy with ... other anti-angiogenic tyrosine kinase inhibitor",
                    "criterion": "prior therapy with other anti-angiogenic tyrosine kinase inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known G6PD deficiency, severe psoriasis, porphyria, macular degeneration, or severe diabetic retinopathy due to greater potential HCQ toxicity",
            "criterions": [
                {
                    "exact_snippets": "Known G6PD deficiency",
                    "criterion": "G6PD deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe psoriasis",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "porphyria",
                    "criterion": "porphyria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "macular degeneration",
                    "criterion": "macular degeneration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe diabetic retinopathy",
                    "criterion": "diabetic retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If a female of childbearing potential, has a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug. If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required. If a patient is of childbearing potential the patient must agree to use effective contraception (see Appendix C for acceptable methods) during the study and for 120 days after the last dose of study drug. Non-childbearing potential is defined as (by other than medical reasons):",
            "criterions": [
                {
                    "exact_snippets": "female of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative serum blood pregnancy test during screening",
                    "criterion": "serum blood pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine pregnancy test within 3 days prior to receiving the first dose of study drug",
                    "criterion": "urine pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days before first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required.",
                    "criterion": "pregnancy test timing substitution",
                    "requirements": [
                        {
                            "requirement_type": "serum test timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days before first dose"
                            }
                        },
                        {
                            "requirement_type": "urine test requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use effective contraception ... during the study and for 120 days after the last dose of study drug",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the study",
                                "for 120 days after the last dose of study drug"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* INR < 2.0",
            "criterions": [
                {
                    "exact_snippets": "INR < 2.0",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients should have received adequate therapy with prior 5-fluorouracil, oxaliplatin, and irinotecan, unless contra-indicated, not tolerated or declined.",
            "criterions": [
                {
                    "exact_snippets": "received adequate therapy with prior 5-fluorouracil",
                    "criterion": "prior 5-fluorouracil therapy",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received adequate therapy with prior ... oxaliplatin",
                    "criterion": "prior oxaliplatin therapy",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received adequate therapy with prior ... irinotecan",
                    "criterion": "prior irinotecan therapy",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Post hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Post hysterectomy",
                    "criterion": "hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Post ... oophorectomy",
                    "criterion": "oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Post ... tubal ligation",
                    "criterion": "tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented hysterectomy ... must be confirmed with medical records of the actual procedure or confirmed by an ultrasound",
                    "criterion": "hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "medical records of the actual procedure",
                                "ultrasound"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented ... oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound",
                    "criterion": "oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "medical records of the actual procedure",
                                "ultrasound"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study drug",
                    "criterion": "tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "medical records of the actual procedure"
                        }
                    ]
                },
                {
                    "exact_snippets": "otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study drug",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use barrier methods",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening visit through 120 days after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease based on modified RECIST 1.1 criteria",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease based on modified RECIST 1.1 criteria",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "modified RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
            "criterions": [
                {
                    "exact_snippets": "Known active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Amenorrheic for <2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation",
            "criterions": [
                {
                    "exact_snippets": "Amenorrheic for <2 years",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without a hysterectomy and oophorectomy",
                    "criterion": "surgical menopause status",
                    "requirements": [
                        {
                            "requirement_type": "hysterectomy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "oophorectomy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation",
                    "criterion": "follicle-stimulating hormone (FSH) value",
                    "requirements": [
                        {
                            "requirement_type": "FSH level",
                            "expected_value": "in the postmenopausal range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >1,500 per uL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >1,500 per uL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1500,
                                "unit": "per uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:",
            "criterions": [
                {
                    "exact_snippets": "History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study",
                    "criterion": "condition, therapy, or laboratory abnormality that might confound study results",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "interfere with the patient's participation for the full duration of the study",
                    "criterion": "condition, therapy, or laboratory abnormality that might interfere with study participation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "is not in the best interest of the patient to participate, in the opinion of the treating Investigator",
                    "criterion": "condition, therapy, or laboratory abnormality not in the best interest of the patient (per Investigator)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Myocardial infarction or arterial thromboembolic events within 6 months prior to screening or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc interval > 470 msec.",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction ... within 6 months prior to screening",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial thromboembolic events within 6 months prior to screening",
                    "criterion": "arterial thromboembolic events",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe or unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "unstable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association (NYHA) Class III or IV disease",
                    "criterion": "NYHA heart failure class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "QTc interval > 470 msec",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients using warfarin are excluded. Patients using other oral or parenteral anticoagulation are not excluded provided they are on a stable dose of anticoagulant but must undergo more frequent platelet count monitoring.",
            "criterions": [
                {
                    "exact_snippets": "Patients using warfarin are excluded",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients using other oral or parenteral anticoagulation are not excluded provided they are on a stable dose of anticoagulant",
                    "criterion": "other oral or parenteral anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "must undergo more frequent platelet count monitoring",
                    "criterion": "platelet count monitoring frequency",
                    "requirements": [
                        {
                            "requirement_type": "frequency",
                            "expected_value": "more frequent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior or current therapy with an HDAC inhibitor",
            "criterions": [
                {
                    "exact_snippets": "No prior or current therapy with an HDAC inhibitor",
                    "criterion": "therapy with an HDAC inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologic or cytologic confirmation of metastatic colorectal cancer",
            "criterions": [
                {
                    "exact_snippets": "Histologic or cytologic confirmation of metastatic colorectal cancer",
                    "criterion": "metastatic colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologic",
                                "cytologic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age 18 years or older",
            "criterions": [
                {
                    "exact_snippets": "Age 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication",
            "criterions": [
                {
                    "exact_snippets": "Evidence or history of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication",
                    "criterion": "hemorrhage or bleeding event",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": "within 4 weeks of start of study medication"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Any prior history of other cancer within the prior 5 years with the exception of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ).",
            "criterions": [
                {
                    "exact_snippets": "Any prior history of other cancer within the prior 5 years",
                    "criterion": "history of other cancer",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ",
                    "criterion": "history of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST and ALT < 2.5 x ULN (< 5 x ULN if documented liver metastases)",
            "criterions": [
                {
                    "exact_snippets": "AST ... < 2.5 x ULN (< 5 x ULN if documented liver metastases)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ... < 2.5 x ULN (< 5 x ULN if documented liver metastases)",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If female, is pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "If female, is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If female, ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine < 1.5 x ULN OR Creatinine clearance (CrCl) > 60 by Cockcroft-Gault Equation if Creatinine >1.5",
            "criterions": [
                {
                    "exact_snippets": "Creatinine < 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Creatinine clearance (CrCl) > 60 by Cockcroft-Gault Equation if Creatinine >1.5",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault Equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.",
            "criterions": [
                {
                    "exact_snippets": "Any contraindication to oral agents",
                    "criterion": "contraindication to oral agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "significant nausea and vomiting",
                    "criterion": "nausea and vomiting",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "not significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption",
                    "criterion": "malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "significant small bowel resection",
                    "criterion": "small bowel resection",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "not significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "that, in the opinion of the investigator, would preclude adequate absorption",
                    "criterion": "adequate absorption",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Another known malignancy that is progressing or requires active treatment.",
            "criterions": [
                {
                    "exact_snippets": "Another known malignancy that is progressing",
                    "criterion": "other known malignancy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "progressing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Another known malignancy that ... requires active treatment",
                    "criterion": "other known malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requires active treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >100,000 per uL",
            "criterions": [
                {
                    "exact_snippets": "Platelets >100,000 per uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100000,
                                "unit": "per uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-healing wound, ulcer, or bone fracture",
            "criterions": [
                {
                    "exact_snippets": "Non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with pre-existing hypertension should be on a stable antihypertensive regimen and have a blood pressure ≤ 150/100 mmHg at the time of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Patients with pre-existing hypertension",
                    "criterion": "pre-existing hypertension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should be on a stable antihypertensive regimen",
                    "criterion": "antihypertensive regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have a blood pressure ≤ 150/100 mmHg at the time of enrollment",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 150,
                                "unit": "mmHg systolic/100 mmHg diastolic"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.",
            "criterions": [
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the study",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Currently participating and receiving study therapy",
                    "criterion": "participation in a study and receiving study therapy",
                    "requirements": [
                        {
                            "requirement_type": "current participation and receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent and received study therapy",
                    "criterion": "prior participation in a study of an investigational agent and receipt of study therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior participation and receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "used an investigational device within 4 weeks of the first dose of study drug",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade <1 (except alopecia or neuropathy). If patient underwent major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.",
            "criterions": [
                {
                    "exact_snippets": "Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade <1 (except alopecia or neuropathy)",
                    "criterion": "toxic effects of most recent prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If patient underwent major surgery ... they must have recovered from the toxicity and/or complications from the intervention",
                    "criterion": "toxicity and/or complications from major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If patient underwent ... radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention",
                    "criterion": "toxicity and/or complications from radiation therapy >30 Gy",
                    "requirements": [
                        {
                            "requirement_type": "radiation dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "Gy"
                            }
                        },
                        {
                            "requirement_type": "recovery",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Exclusion Criteria",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}